Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 8.01 (Other Events), Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). ATM program upsized March 2, 2026 from $750M to ~$1.035B total capacity; $400M in new shares available for sale.
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- ATM program upsized March 2, 2026 from $750M to ~$1.035B total capacity; $400M in new shares available for sale
- Already sold ~$635M of shares under prior tranches: significant dilution already absorbed by existing shareholders
- New $400M tranche includes ~$114.7M of unsold capacity rolled over from prior prospectus; net new capacity ~$285M
- Jefferies acts as agent on best-efforts basis at 3% commission on gross proceeds; no obligation to sell any shares
- Ongoing ATM overhang of up to $400M in potential share issuance pressures stock: typical for cash-burning biotech managing runway
Item 7.01 · Regulation FD Disclosure
- FDA lifted clinical hold on MAGNITUDE Phase 3 trial for ATTR-CM (transthyretin amyloid cardiomyopathy), removing a key regulatory overhang
- Clinical hold removal allows Intellia to resume/initiate patient enrollment in its pivotal cardiac gene editing trial: critical gating event for NTLA's pipeline
- ATTR-CM is a large commercial opportunity; Phase 3 restart directly de-risks the program and accelerates potential path to approval
Item 8.01 · Other Events
- FDA lifted clinical hold on MAGNITUDE Phase 3 trial (ATTR-CM) as of March 2, 2026: trial enrollment can resume
- Hold was imposed Oct 29, 2025 after Grade 4 liver transaminase elevation + increased bilirubin in a dosed patient: ~4-month disruption
- Mitigation measures include enhanced liver monitoring, short-term steroids protocol, and exclusion of patients with liver abnormalities or ejection fraction <25%
- MAGNITUDE-2 (ATTRv-PN) hold status not explicitly lifted: Intellia still "engaged with stakeholders" to resume, suggesting regulatory resolution may lag MAGNITUDE
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.